FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2110167268> ?p ?o ?g. }

• W2110167268 endingPage "298S" @default.
• W2110167268 startingPage "257S" @default.
• W2110167268 abstract "This article about hemorrhagic complications of anticoagulant and thrombolytic treatment is part of the Antithrombotic and Thrombolytic Therapy: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). Bleeding is the major complication of anticoagulant and fibrinolytic therapy. The criteria for defining the severity of bleeding vary considerably between studies, accounting in part for the variation in the rates of bleeding reported. The major determinants of vitamin K antagonist (VKA)-induced bleeding are the intensity of the anticoagulant effect, underlying patient characteristics, and the length of therapy. There is good evidence that VKA therapy, targeted international normalized ratio (INR) of 2.5 (range, 2.0-3.0), is associated with a lower risk of bleeding than therapy targeted at an INR > 3.0. The risk of bleeding associated with IV unfractionated heparin (UFH) in patients with acute venous thromboembolism is < 3% in recent trials. This bleeding risk may increase with increasing heparin dosages and age (> 70 years). Low-molecular-weight heparin (LMWH) is associated with less major bleeding compared with UFH in acute venous thromboembolism. Higher doses of UFH and LMWH are associated with important increases in major bleeding in ischemic stroke. In ST-segment elevation myocardial infarction, addition of LMWH, hirudin, or its derivatives to thrombolytic therapy is associated with a small increase in the risk of major bleeding, whereas treatment with fondaparinux or UFH is associated with a lower risk of bleeding. Thrombolytic therapy increases the risk of major bleeding 1.5-fold to threefold in patients with acute venous thromboembolism, ischemic stroke, or ST-elevation myocardial infarction. This article about hemorrhagic complications of anticoagulant and thrombolytic treatment is part of the Antithrombotic and Thrombolytic Therapy: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). Bleeding is the major complication of anticoagulant and fibrinolytic therapy. The criteria for defining the severity of bleeding vary considerably between studies, accounting in part for the variation in the rates of bleeding reported. The major determinants of vitamin K antagonist (VKA)-induced bleeding are the intensity of the anticoagulant effect, underlying patient characteristics, and the length of therapy. There is good evidence that VKA therapy, targeted international normalized ratio (INR) of 2.5 (range, 2.0-3.0), is associated with a lower risk of bleeding than therapy targeted at an INR > 3.0. The risk of bleeding associated with IV unfractionated heparin (UFH) in patients with acute venous thromboembolism is < 3% in recent trials. This bleeding risk may increase with increasing heparin dosages and age (> 70 years). Low-molecular-weight heparin (LMWH) is associated with less major bleeding compared with UFH in acute venous thromboembolism. Higher doses of UFH and LMWH are associated with important increases in major bleeding in ischemic stroke. In ST-segment elevation myocardial infarction, addition of LMWH, hirudin, or its derivatives to thrombolytic therapy is associated with a small increase in the risk of major bleeding, whereas treatment with fondaparinux or UFH is associated with a lower risk of bleeding. Thrombolytic therapy increases the risk of major bleeding 1.5-fold to threefold in patients with acute venous thromboembolism, ischemic stroke, or ST-elevation myocardial infarction." @default.
• W2110167268 created "2016-06-24" @default.
• W2110167268 creator A5002200808 @default.
• W2110167268 creator A5013493617 @default.
• W2110167268 creator A5014971710 @default.
• W2110167268 creator A5083115765 @default.
• W2110167268 date "2008-06-01" @default.
• W2110167268 modified "2023-10-17" @default.
• W2110167268 title "Hemorrhagic Complications of Anticoagulant and Thrombolytic Treatment" @default.
• W2110167268 cites W101335387 @default.
• W2110167268 cites W1260428 @default.
• W2110167268 cites W131809637 @default.
• W2110167268 cites W137180508 @default.
• W2110167268 cites W1484129406 @default.
• W2110167268 cites W1485646988 @default.
• W2110167268 cites W1498265361 @default.
• W2110167268 cites W1522694313 @default.
• W2110167268 cites W1533600198 @default.
• W2110167268 cites W1558642892 @default.
• W2110167268 cites W1565918379 @default.
• W2110167268 cites W156816327 @default.
• W2110167268 cites W1568597842 @default.
• W2110167268 cites W1581187193 @default.
• W2110167268 cites W1583091879 @default.
• W2110167268 cites W1585004555 @default.
• W2110167268 cites W1586895761 @default.
• W2110167268 cites W1592274831 @default.
• W2110167268 cites W1596397105 @default.
• W2110167268 cites W160665858 @default.
• W2110167268 cites W1647537909 @default.
• W2110167268 cites W1715733843 @default.
• W2110167268 cites W173036589 @default.
• W2110167268 cites W1763204026 @default.
• W2110167268 cites W1804375307 @default.
• W2110167268 cites W1875541132 @default.
• W2110167268 cites W1884186391 @default.
• W2110167268 cites W1889263859 @default.
• W2110167268 cites W1918936479 @default.
• W2110167268 cites W1954469645 @default.
• W2110167268 cites W1957588549 @default.
• W2110167268 cites W1965043503 @default.
• W2110167268 cites W1966287165 @default.
• W2110167268 cites W1967181084 @default.
• W2110167268 cites W1967937963 @default.
• W2110167268 cites W1969266021 @default.
• W2110167268 cites W1971119013 @default.
• W2110167268 cites W1972083038 @default.
• W2110167268 cites W1972706485 @default.
• W2110167268 cites W1975170689 @default.
• W2110167268 cites W1976237679 @default.
• W2110167268 cites W1979245531 @default.
• W2110167268 cites W1979288586 @default.
• W2110167268 cites W1979363567 @default.
• W2110167268 cites W1981746689 @default.
• W2110167268 cites W1981816788 @default.
• W2110167268 cites W1982830772 @default.
• W2110167268 cites W1984307144 @default.
• W2110167268 cites W1984597181 @default.
• W2110167268 cites W1984833612 @default.
• W2110167268 cites W1986174344 @default.
• W2110167268 cites W1986506316 @default.
• W2110167268 cites W1987034302 @default.
• W2110167268 cites W1989192399 @default.
• W2110167268 cites W1991549653 @default.
• W2110167268 cites W1992159512 @default.
• W2110167268 cites W1992377235 @default.
• W2110167268 cites W1992460911 @default.
• W2110167268 cites W1992492980 @default.
• W2110167268 cites W1992661527 @default.
• W2110167268 cites W1994894525 @default.
• W2110167268 cites W1995192108 @default.
• W2110167268 cites W1997667641 @default.
• W2110167268 cites W1999206854 @default.
• W2110167268 cites W1999810593 @default.
• W2110167268 cites W2001285874 @default.
• W2110167268 cites W2004337162 @default.
• W2110167268 cites W2005615751 @default.
• W2110167268 cites W2006149651 @default.
• W2110167268 cites W2006587134 @default.
• W2110167268 cites W2007303097 @default.
• W2110167268 cites W2007650238 @default.
• W2110167268 cites W2009013630 @default.
• W2110167268 cites W2010280774 @default.
• W2110167268 cites W2010836948 @default.
• W2110167268 cites W2011532714 @default.
• W2110167268 cites W2012714913 @default.
• W2110167268 cites W2013749044 @default.
• W2110167268 cites W2015696505 @default.
• W2110167268 cites W2016844884 @default.
• W2110167268 cites W2017836681 @default.
• W2110167268 cites W2018787470 @default.
• W2110167268 cites W2019678690 @default.
• W2110167268 cites W2021951293 @default.
• W2110167268 cites W2025513998 @default.
• W2110167268 cites W2025954547 @default.
• W2110167268 cites W2026589095 @default.
• W2110167268 cites W2027151097 @default.
• W2110167268 cites W2027467473 @default.

• next